Actionable insights straight to your inbox

Equities logo

Asterias Biotherapeutics, Inc. Files SEC Form 424B3, Prospectus [Rule 424(B)(3)] (Jun. 26, 2014)

By a News Reporter-Staff News Editor at Life Science Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC)

By a News Reporter-Staff News Editor at Life Science Weekly — According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Asterias Biotherapeutics, Inc. (Form 424B3) was posted on June 26, 2014.
The SIC code for this company is 2836, Biological Products, (No Diagnostic Substances).
There were 3 documents filed with this form. The SEC file number is 0001140361-14-026796.
The contact information for this company is 230 CONSTITUTION DRIVE, MENLO PARK CA 94025, 510-521-3390.
Our editors provided additional information about Form 424B3: Final prospectus filed pursuant to Rule 424(b)(3).
A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.
For additional information on this SEC filing see: http://www.sec.gov/Archives/edgar/data/1572552/0001140361-14-026796-index.html.
Keywords for this news article include: SEC Filing, Biological Products, (No Diagnostic Substances), Asterias Biotherapeutics Inc..
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

The saying that there is no such thing as a free lunch is very much true for Robinhood.